Sartorius Stedim: Quarterly EPS more than halved

(CercleFinance.com) - Sartorius Stedim Biotech (SSB) reports EPS of E0.
58 for Q1 2024, compared with E1.21 a year earlier, while recurring EBITDA fell 13.2% to E191m, i.e. a margin of 28.6%, vs. 30.3% for Q1 2023.

The supplier of products and services to the pharmaceutical industry posted sales of E667m, down 6.7% at constant exchange rates, although booked orders of E676m, up 13.9% at constant exchange rates.

For 2024, SSB still expects a gradual recovery in business sequentially, looking for expects sales growth in the mid-to-high single digits, as well as a current EBITDA margin of over 30%.


Copyright (c) 2024 CercleFinance.com. All rights reserved.